Modification of Sample Size in Group Sequential Clinical Trials
- 1 September 1999
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 55 (3) , 853-857
- https://doi.org/10.1111/j.0006-341x.1999.00853.x
Abstract
Summary. In group sequential clinical trials, sample size reestimation can be a complicated issue when it allows for change of sample size to be influenced by an observed sample path. Our simulation studies show that increasing sample size based on an interim estimate of the treatment difference can substantially inflate the probability of type I error in most practical situations. A new group sequential test procedure is developed by modifying the weights used in the traditional repeated significance two‐sample mean test. The new test has the type I error probability preserved at the target level and can provide a substantial gain in power with the increase of sample size. Generalization of the new procedure is discussed.Keywords
This publication has 14 references indexed in Scilit:
- Sample Size Reestimation for Triple Blind Clinical TrialsDrug Information Journal, 1993
- Interim analyses for monitoring clinical trials that do not materially affect the type I error rateStatistics in Medicine, 1992
- Sample size re-estimation without unblinding for normally distributed outcomes with unknown varianceCommunications in Statistics - Theory and Methods, 1992
- The role of internal pilot studies in increasing the efficiency of clinical trialsStatistics in Medicine, 1990
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983
- Group sequential methods in the design and analysis of clinical trialsBiometrika, 1977